Xeris Biopharma Holdings
XERS
93 hedge funds and large institutions have $115M invested in Xeris Biopharma Holdings in 2021 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 20 increasing their positions, 35 reducing their positions, and 35 closing their positions.
272% more call options, than puts
Call options by funds: $8.9M | Put options by funds: $2.39M
7.63% less ownership
Funds ownership: 50.05% → 42.42% (-7.6%)
10% less funds holding
Funds holding: 103 → 93 (-10)
23% less capital invested
Capital invested by funds: $150M → $115M (-$34.7M)
29% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 35
43% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.08M |
| 2 |
SG Americas Securities
New York
|
+$932K |
| 3 |
SC
Sessa Capital
New York
|
+$927K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$894K |
| 5 |
Renaissance Technologies
New York
|
+$683K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$7.94M |
| 2 |
D.E. Shaw & Co
New York
|
-$2.76M |
| 3 |
State Street
Boston,
Massachusetts
|
-$2.17M |
| 4 |
TA
Tamarack Advisers
Carlsbad,
California
|
-$1.58M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$1.4M |
XERS Hedge Fund Activity: Q2 2021 in Review
93 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q2 2021, worth a combined $115M — down 23% from $150M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of XERS and 25 opened new positions — a net loss of 10 holders — while 35 trimmed existing stakes and 20 added.
The largest buyer was Millennium Management, adding an estimated $1.08M. The largest seller was BlackRock, cutting an estimated $7.94M.
- 93 institutional investors held Xeris Biopharma Holdings (XERS) as of Q2 2021, down from 103 in Q1 2021.
- Funds reported $115M of Xeris Biopharma Holdings stock for Q2 2021, down 23% quarter-over-quarter.
- 25 funds opened new Xeris Biopharma Holdings positions in Q2 2021 and 35 closed out, a net change of -10 holders.
- The largest Xeris Biopharma Holdings buyer in Q2 2021 was Millennium Management, an estimated $1.08M added.
- The largest Xeris Biopharma Holdings seller in Q2 2021 was BlackRock, an estimated $7.94M sold.
Based on aggregated 13F filings for Q2 2021.